Correlation Between Crispr Therapeutics and BioNTech

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and BioNTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and BioNTech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and BioNTech SE, you can compare the effects of market volatilities on Crispr Therapeutics and BioNTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of BioNTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and BioNTech.

Diversification Opportunities for Crispr Therapeutics and BioNTech

0.25

Correlation Coefficient

Crispr Therapeutics  BioNTech

Modest diversification

The 3 months correlation between Crispr and BioNTech is 0.25. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and BioNTech SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioNTech SE and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with BioNTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioNTech SE has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and BioNTech go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and BioNTech

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to under-perform the BioNTech. In addition to that, Crispr Therapeutics is 1.22 times more volatile than BioNTech SE. It trades about -0.08 of its total potential returns per unit of risk. BioNTech SE is currently generating about 0.0 per unit of volatility. If you would invest  11,720  in BioNTech SE on December 1, 2024 and sell it today you would lose (428.00) from holding BioNTech SE or give up 3.65% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  BioNTech SE

Crispr Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Crispr Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

BioNTech SE

Risk-Adjusted Performance

Very Weak

Over the last 90 days BioNTech SE has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, BioNTech is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Crispr Therapeutics and BioNTech

The main advantage of trading using opposite Crispr Therapeutics and BioNTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, BioNTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will offset losses from the drop in BioNTech's long position.

The idea behind Crispr Therapeutics AG and BioNTech SE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.